This hypothetical mechanism could explain, at least in part, the increased survival seen by Urup et al. [52] in those recurrent GBM patients with low expression of AGT when they were treated with BVZ, and also might be the reason for the poor prognosis that was seen in the patients harboring GG-genotype (and not treated with BVZ) in our study. The gene discussed is AGT; the disease is glioblastoma.